Triagem de voluntários saudáveis para medicamentos antimaláricos em investigação, vacinas contra a malária e desafio contra a malária humana controlada
Background:
Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in places were malaria is common, such as Africa but can also affect travelers who have never been exposed to malaria. Researchers at the NIH want to find a safe and effective malaria vaccine, antimalarial drugs, or prevention regimen. To do this, healthy volunteers are recruited under a general screening study in order to see if are qualified to join a future malaria study.
Objective:
To screen healthy volunteers to see if they are eligible to join investigational malaria studies. The studies will be trials of investigational antimalarial drugs, malaria vaccines, or prevention regimens. They may also involve controlled human malaria infection trials.
Eligibility:
Healthy people ages 18 50
Design:
Participants will first be prescreened by phone.
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Participants may go more than 1 year without joining a clinical trial. If this happens, they may be re-contacted to see if they still want to be part of this screening protocol. Those who still want to participate and have had relevant medical changes will be rescreened.
Visão geral do estudo
Status
Status
Condições
Condições
Descrição detalhada
This is a screening protocol for healthy volunteers to participate in research studies conducted by Laboratory of Malaria Immunology and Vaccinology (LMIV).
Malaria-related morbidity and mortality have a major economic impact in endemic regions and
present a substantial health risk to non-immune travelers and people living in endemic areas. To stem the worldwide impact of this devastating disease, a safe and broadly effective malaria vaccine and improved antimalarial therapeutics are urgently required.
This screening protocol is designed to continuously evaluate potential healthy volunteers to build a pool of volunteers who may participate in future and ongoing LMIV malaria drug, vaccine, or controlled human malaria infections (CHMI) trials. A complete medical history and blood and urine samples will be obtained to evaluate whether volunteers are eligible for study-specific screening.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: David M Cook, M.D.
- Número de telefone: (240) 627-3066
- E-mail: cookdm@mail.nih.gov
Locais de estudo
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- Recrutamento
- National Institutes of Health Clinical Center
-
Contato:
- For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
- Número de telefone: 888-624-1937
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
healthy volunteers in the Washington, DC region
Descrição
- INCLUSION CRITERIA:
All of the following criteria must be fulfilled for a subject to participate in this trial:
- Age >= 18 and <= 50 years.
- In good general health and without clinically significant medical history
- Reliable access to the clinical trial center and available in the area for more than 1 year
- Females of childbearing potential must be willing to undergo periodic pregnancy testing and use reliable contraception per protocol when enrolled into LMIV clinical trials (protocol-specific requirements)
EXCLUSION CRITERIA:
A subject will be excluded from participating in this trial if any one of the following criteria is fulfilled:
-
Pregnant, breastfeeding, or planned pregnancy in the upcoming year.
-
Hemoglobin, white blood cell (WBC), platelets, alanine transaminase (ALT), and creatinine (Cr) outside of local lab normal range (subjects may be included at the investigator's discretion for "not clinically significant" values outside of normal range).
-
Anticipated use during the study period, or use within the following periods prior to enrollment:
- Investigational malaria vaccine within the last five years
- Chronic systemic immunosuppressive medications (e.g., cytotoxic medications, oral/parental corticosteroids > 0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis is allowed.
- Recurrent receipt of blood products or immunoglobulins
-
History of:
- Sickle cell disease
- Splenectomy or functional asplenia
- Systemic anaphylaxis
- Uncontrolled psoriasis or porphyria
-
Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:
- A process that would affect the immune response, or requires medication that affects the immune response.
- Any contraindication to repeated phlebotomy.
-
History of or known active cardiac disease including:
- prior myocardial infarction (heart attack)
- angina pectoris
- congestive heart failure
- valvular heart disease
- cardiomyopathy
- pericarditis
- stroke or transient ischemic attack
- exertional chest pain or shortness of breath
- other heart conditions under the care of a doctor
-
Infection with HIV, hepatitis B, and/or hepatitis C
-
Psychiatric condition that precludes compliance with the protocol including but not limited to:
- Psychosis within the past 3 years
- Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years
-
Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the discretion of the PI
-
Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject's ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: CROSS_SECTIONAL
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
|---|
|
Healthy volunteer
healthy, malaria-na(SqrRoot) ve US adults |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To screen healthy volunteers for future malaria studies
Prazo: 1 year
|
identify healthy adults at a low risk of developing complications due to experimental malaria infection, investigational antimalarials and vaccines |
1 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: David M Cook, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 160039
- 16-I-0039
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
This is a screening protocol for healthy volunteers to participate in research studies conducted by Laboratory of Malaria Immunology and Vaccinology (LMIV).@@@@@@@@@@@@This screening protocol is designed to evaluate potential healthy volunteers to build a pool of volunteers who may participate in future and ongoing LMIV malaria drug, vaccine, or controlled human malaria infections (CHMI) trials. Data obtained for individual subjects will used not be used for direct research purposes on this study; therefore we will not make IPD available at this time.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .